Research records indexed for Eloralintide
This page carries 7 of the 10 records that the literature query returned for Eloralintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 3 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Eloralintide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept pmid:41559929 | 2026 | research-article, Multicenter Study | human trial | Not stated | Indexed as research-article, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Injections, Subcutaneous; Amylin Receptor Agonists. |
| Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes pmid:41747885 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptides; Islet Amyloid Polypeptide. |
| Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials pmid:42452898 | 2026 | research-article, Review | other | Not stated | Indexed as research-article, review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Clinical Trials As Topic; Islet Amyloid Polypeptide. |
| Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs pmid:42586227 | 2026 | Review | other | Not stated | Indexed as review. compound named in the abstract, not the title. study model from MeSH "Animals" with no rodent species heading. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Islet Amyloid Polypeptide; Amylin Receptor Agonists. |
| Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis pmid:42175595 | 2026 | review-article, Review | other | Not stated | Indexed as review-article, review. compound named in the abstract, not the title. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Overweight; Randomized Controlled Trials As Topic. |
| Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial pmid:41207310 | 2025 | Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase ii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Obesity; Weight Loss; Anti-Obesity Agents; Amylin Receptor Agonists. |
| Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept pmid:41109426 | 2025 | research-article, Clinical Trial, Phase I | human trial | Not stated | Indexed as research-article, clinical trial, phase i. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Rats, Sprague-Dawley; Obesity; Anti-Obesity Agents; Islet Amyloid Polypeptide; Receptors, Islet Amyloid Polypeptide. |
Where this page sits
Compound page: Eloralintide. Class: Amylin and amylin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 175663130, Eloralintide. PubChem, National Library of Medicine (2026). pubchem:175663130
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:eloralintide
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular metabolism (2025). pmid:41109426
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, obesity & metabolism (2026). pmid:41559929
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310
- Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide. Cardiology in review (2026). pmid:42745233
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.